{
  "openalex_id": "W2796301229",
  "doi": "https://doi.org/10.1016/j.juro.2018.02.2555",
  "title": "MP78-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA",
  "abstract": "You have accessJournal of UrologyBladder Cancer: Invasive VI1 Apr 2018MP78-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA Richard W. Joseph, Yohann Loriot, Jose Luis Perez-Gracia, Robert Dreicer, Daniel P. Petrylak, Michiel S. van der Heijden, Jean Hoffman-Censits, Xiadong Shen, Simon Fear, Julie Pavlova, and Jonathan E. Rosenberg Richard W. JosephRichard W. Joseph More articles by this author , Yohann LoriotYohann Loriot More articles by this author , Jose Luis Perez-GraciaJose Luis Perez-Gracia More articles by this author , Robert DreicerRobert Dreicer More articles by this author , Daniel P. PetrylakDaniel P. Petrylak More articles by this author , Michiel S. van der HeijdenMichiel S. van der Heijden More articles by this author , Jean Hoffman-CensitsJean Hoffman-Censits More articles by this author , Xiadong ShenXiadong Shen More articles by this author , Simon FearSimon Fear More articles by this author , Julie PavlovaJulie Pavlova More articles by this author , and Jonathan E. RosenbergJonathan E. Rosenberg More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2555AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Atezolizumab (atezo) is an anti-PD-L1 checkpoint inhibitor approved in the US and Europe as 1L therapy for cisplatin (cis)-ineligible patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) and in the platinum-treated setting. While many pts derive clinical benefit, a subset can develop early progression during treatment. The goal of this post hoc analysis was to assess the percentage of IMvigor210 pts with progressive disease (PD) at first assessment (wk 9) and to identify clinical characteristics that may differentiate early progressors from responders. METHODS In IMvigor210 Cohort 2 (NCT02108652), mUC pts who progressed during or following platinum received atezo 1200 mg IV q3w until loss of clinical benefit per investigator. Baseline characteristics, including known prognostic factors, and mOS were descriptively evaluated in subgroups based on RECIST v1.1 (per independent review facility; IRF) best overall response (BOR) and PD events at wk 9 and 1 y. RESULTS 310 Cohort 2 pts were evaluable, and baseline characteristics by BOR and PD status at either 1 y or first tumor assessment (wk 9) are included in the Table. Pts who experienced RECIST v1.1 PD at wk 9 (n = 167) or at 1 y (n = 264) tended to present with liver mets, low Hbg (< 10 g/dL), ECOG PS > 0 and greater tumor burden (per sum of target lesion diameters [SLD]; Table), while no trend in new lesion patterns was seen. With a median follow-up of 21.0 mo (range, 0.2+ to 24.5), mOS was 3.9 mo (95% CI: 3.2, 5.8) in pts with PD at wk 9 (n = 167) and 17.3 mo (95% CI: 13.3, 21.8) in pts without PD at wk 9 (n = 140). Aside from ECOG PS, similar baseline characteristic and OS trends occurred in cis-ineligible pts treated with 1L atezo (Cohort 1). Additional analyses will be presented. CONCLUSIONS In IMvigor210 mUC pts, baseline clinical factors, including liver mets, low Hbg, high tumor burden and ECOG PS > 0, may be associated with PD by wk 9 on study, and pts without progression by wk 9 may experience long-term OS benefit with atezo. Further characterization of correlates of overall clinical benefit and early PD is warranted--with cancer immunotherapy and for rapidly progressing pts treated with other therapeutic options. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1039 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Richard W. Joseph More articles by this author Yohann Loriot More articles by this author Jose Luis Perez-Gracia More articles by this author Robert Dreicer More articles by this author Daniel P. Petrylak More articles by this author Michiel S. van der Heijden More articles by this author Jean Hoffman-Censits More articles by this author Xiadong Shen More articles by this author Simon Fear More articles by this author Julie Pavlova More articles by this author Jonathan E. Rosenberg More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...",
  "authors": [
    {
      "display_name": "Richard W. Joseph",
      "id": "A5034715033",
      "orcid": "https://orcid.org/0000-0001-6102-4661",
      "institutions": [
        {
          "id": "I36075867",
          "display_name": "Jacksonville University",
          "country_code": "US",
          "type": "education"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Richard W. Joseph"
    },
    {
      "display_name": "Yohann Loriot",
      "id": "A5027991868",
      "orcid": "https://orcid.org/0000-0002-8338-1739",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Yohann Loriot"
    },
    {
      "display_name": "Jose Luis Pérez‐Gracia",
      "id": "A5044557306",
      "orcid": "https://orcid.org/0000-0003-4941-9075",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Jose Luis Perez-Gracia"
    },
    {
      "display_name": "Robert Dreicer",
      "id": "A5110299074",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127285",
          "display_name": "Charlottesville Medical Research",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Robert Dreicer"
    },
    {
      "display_name": "Daniel P. Petrylak",
      "id": "A5050042851",
      "orcid": "https://orcid.org/0000-0001-6165-5797",
      "institutions": [
        {
          "id": "I40253897",
          "display_name": "University of New Haven",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Daniel P. Petrylak"
    },
    {
      "display_name": "Michiel S. van der Heijden",
      "id": "A5031163075",
      "orcid": "https://orcid.org/0000-0002-4407-7881",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Michiel S. van der Heijden"
    },
    {
      "display_name": "Jean Hoffman‐Censits",
      "id": "A5044979250",
      "orcid": "https://orcid.org/0000-0002-6970-6509",
      "institutions": [
        {
          "id": "I922845939",
          "display_name": "Philadelphia University",
          "country_code": "US",
          "type": "education"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jean Hoffman-Censits"
    },
    {
      "display_name": "Xiadong Shen",
      "id": "A5043140595",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210134442",
          "display_name": "Kaiser Permanente South San Francisco Medical Center",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Xiadong Shen"
    },
    {
      "display_name": "Simon Fear",
      "id": "A5090663639",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Simon Fear"
    },
    {
      "display_name": "Julie Pavlova",
      "id": "A5084083136",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Julie Pavlova"
    },
    {
      "display_name": "Jacob Rosenberg",
      "id": "A5029777782",
      "orcid": "https://orcid.org/0000-0002-0063-1086",
      "institutions": [
        {
          "id": "I4210107408",
          "display_name": "New York Proton Center",
          "country_code": "US",
          "type": "facility"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jonathan E. Rosenberg"
    }
  ],
  "publication_year": 2018,
  "publication_date": "2018-04-01",
  "type": "article",
  "cited_by_count": 5,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S30525748",
    "display_name": "The Journal of Urology",
    "issn_l": "0022-5347",
    "issn": [
      "0022-5347",
      "1527-3792"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310315671"
  },
  "volume": "199",
  "issue": "4S",
  "first_page": null,
  "last_page": null,
  "open_access": {
    "is_oa": true,
    "oa_status": "bronze",
    "oa_url": "https://www.auajournals.org/doi/pdf/10.1016/j.juro.2018.02.2555",
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C2775949291",
      "display_name": "Atezolizumab",
      "level": 5,
      "score": 0.903757
    },
    {
      "id": "C2911057145",
      "display_name": "Metastatic Urothelial Carcinoma",
      "level": 5,
      "score": 0.8353907
    },
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.8319876
    },
    {
      "id": "C143998085",
      "display_name": "Oncology",
      "level": 1,
      "score": 0.4889487
    },
    {
      "id": "C3019882237",
      "display_name": "Urothelial carcinoma",
      "level": 4,
      "score": 0.4250994
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.35983545
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.34666938
    },
    {
      "id": "C2780352672",
      "display_name": "Bladder cancer",
      "level": 3,
      "score": 0.18515596
    },
    {
      "id": "C2777701055",
      "display_name": "Immunotherapy",
      "level": 3,
      "score": 0.1593731
    },
    {
      "id": "C2780030458",
      "display_name": "Nivolumab",
      "level": 4,
      "score": 0.07609546
    }
  ],
  "topics": [
    {
      "id": "T10458",
      "display_name": "Bladder and Urothelial Cancer Treatments",
      "score": 0.9997
    },
    {
      "id": "T10158",
      "display_name": "Cancer Immunotherapy and Biomarkers",
      "score": 0.9942
    },
    {
      "id": "T12695",
      "display_name": "Urinary and Genital Oncology Studies",
      "score": 0.9786
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1016/j.juro.2018.02.2555",
  "pdf_url": "https://www.auajournals.org/doi/pdf/10.1016/j.juro.2018.02.2555",
  "retrieved_date": "2025-07-30T15:28:52.049466",
  "source_database": "OpenAlex"
}